CG Oncology CGON Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about CG Oncology's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CG Oncology's accrued expenses?
- CG Oncology (CGON) reported accrued expenses of $25.91M in Q1 2026.
- How has CG Oncology's accrued expenses changed year-over-year?
- CG Oncology's accrued expenses increased by 65.5% year-over-year, from $15.66M to $25.91M.
- What is the long-term trend for CG Oncology's accrued expenses?
- Over 2 years (2023 to 2025), CG Oncology's accrued expenses has grown at a 52.3% compound annual growth rate (CAGR), from $10.44M to $24.21M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.